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The function of p53 is modulated by several transcriptional coactivators that regulate its tumor suppressor
activity. Here we report that human transcriptional coactivator PC4 enhances the DNA binding of p53 to its
cognate site in vitro and directly interacts with p53 in vivo. In vitro interaction studies demonstrated that the
C-terminal 30 amino acids (364 to 393) of p53 strongly interact with PC4. Surprisingly, PC4 also stimulates
the sequence-specific DNA binding of p53 with the C-terminal 30 amino acids deleted (p5330), suggesting
that PC4 mediates enhancement of p53 DNA binding by a unique mechanism. We also demonstrated that PC4
can stimulate p53- and p5330-mediated transactivation from a p53-responsive promoter. Furthermore, PC4
enhances p53- and p5330-dependent apoptosis by inducing bax (a p53-targeted proapoptotic gene) gene
expression. These results establish the first physiological role of PC4 as a transcriptional coactivator.
p53 exerts its tumor suppressor activity by regulating the
transcription of several factors, which in turn modulate cell
cycle and apoptotic pathways during genotoxic insult. Several
transcription factors and coactivators are involved in the main-
tenance of stability and the regulation of p53 function. p53 has
been shown to interact with a number of proteins implicated in
transcriptional control, such as TAF9, TAF6, and hTAF9 (20).
Interestingly, the coactivator protein hTAF9 binds to p53 at
the amino-terminal region in competition with MDM2 (re-
quired for degradation of p53 through the ubiqutin-proteo-
some pathway) and stabilizes p53 during conditions of stress
(4). It is also reported that the interaction of p53 with either
recombinant TBP or partially purified TFIID stimulates bind-
ing to its cognate site and results in the enhancement of tran-
scription in vivo (7). In another study it has been shown that
squelching of in vitro transcription by excess p53 is alleviated
by the addition of TFIIB and TFIID (25). This suggests that
interaction with these factors plays an important role in p53-
regulated transcription.
Apart from interacting with the basal transcription machin-
ery, p53 interacts with several other transcriptional coactiva-
tors with functional consequences. These include p300/CBP (2,
10, 24, 32), Zac1 (zinc finger protein which regulates apoptosis
and cell cycle) (15), JMY (junction-mediating and regulatory
protein) (32), and HMG-B1 (high-mobility-group protein B-1)
(16). Zac1 specifically enhances the activity of a p53-responsive
promoter in cells expressing wild-type p53. Zac1 was also
shown to interact with human papillomavirus protein E6, re-
sponsible for p53 degradation in HeLa cells, resulting in sta-
bilization of p53 (15). CBP/p300, which is implicated in cell
proliferation and differentiation, has been shown to activate
transcription synergistically with p53 (10). JMY forms a com-
plex with p300 during stress conditions and acts as a coactiva-
tor for p53 to activate transcription of bax, a p53 target gene
that activates apoptosis (32). The highly abundant nonhistone
chromatin protein HMGB-1, a transcriptional coactivator, is a
unique activator of p53-mediated DNA binding and transcrip-
tional activation (16). Interestingly, the human transcriptional
coactivator PC4 (positive coactivator 4) displays significant
functional homology to HMGB-1. For example, similar to
HMGB-1, PC4 binds to DNA in a sequence-independent man-
ner and is involved in diverse nuclear processes (e.g., polymer-
ase III transcription, elongation, and AP2 self-repression) be-
sides RNA polymerase II-mediated transcription (5, 9, 12, 13,
17, 18, 21, 33, 34).
PC4 is a highly abundant nuclear protein which facilitates
activator-dependent transcription by RNA polymerase II
through interactions with the basal transcription machinery
and transcriptional activators like GAL4-BRCA1, GAL4-
VP16, GAL4-CTF1, GAL4-Sp1, and AP2 (9, 14, 18). Presum-
ably by stimulating activator-dependent transcription, PC4
plays a critical role in the maintenance of normal cellular
growth. It has been shown that PC4 can inhibit AP2 self-
repression in a ras-transformed cell line and thus may act as a
putative tumor suppressor (18). Correlating this fact with the
observation that PC4 also activates tumor suppressor BRCA1-
dependent transcription, we hypothesized that PC4 may be
involved in p53-dependent transcriptional regulation to main-
tain cellular homeostasis.
In this study, we investigated the possible role of PC4 in the
modulation of p53 function. We observed that PC4 indeed
stimulates the sequence-specific DNA binding ability of p53 in
vitro. Immunoprecipitation of p53 from drug (adriamycin)-
treated U2OS cells showed that PC4 interacts with p53 in vivo.
By employing a glutathione S-transferase (GST) pulldown as-
say, we determined that the C-terminal 30 amino acids (364 to
393) of p53 are involved in the interaction with PC4. Further-
more, electrophoretic mobility shift assay (EMSA) analysis
revealed that PC4 could also stimulate the DNA binding of a
consecutively active form of p53, which carries a deletion of the
C-terminal 30 amino acids (364 to 393), thus indicating that the
PC4-mediated enhancement of p53 DNA binding is unique.
Our data also show that PC4 can stimulate both p53- and
p5330-mediated reporter gene expression from p53-respon-
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sive promoters. Significantly, PC4 activates p53-dependent apo-
ptosis through the induction of bax, a p53-targeted proapopto-
tic gene. Taken together, the data establish the physiological
relevance of stimulation of p53-dependent DNA binding and
subsequent transcriptional activation by PC4, a general tran-
scriptional coactivator.
MATERIALS AND METHODS
Plasmid construction. The mammalian expression clone of full-length PC4
was constructed by PCR-based subcloning, using appropriate primers, into NheI
and HindIII sites of the pcDNA 3.1 () vector (Invitrogen). The FLAG-tagged
bacterial expression clone of p5330 was constructed by PCR-based subcloning,
using appropriate primers (containing the nucleotide sequence for the FLAG
peptide at the 5 end), from a full-length p53 clone (11). The same strategy was
followed to clone full-length p53 and p5330 into the EcoRI and BamHI sites of
the pIRES puro (Clonetech) mammalian expression vector.
Purification of recombinant proteins. Recombinant PC4 was expressed and
purified from Escherichia coli as described elsewhere (9). FLAG-tagged p53 was
purified from E. coli as described elsewhere (11) with minor modifications.
FLAG-tagged p5330 and Gal4-CTF1 were purified from E. coli by using the
same protocol as that described elsewhere (23). The authenticity of both the
full-length p53 and p53 with the C terminus deleted (p5330) was confirmed by
Western blotting using N-terminus-specific (DO1) and C-terminus-specific
(PAb421) p53 monoclonal antibodies.
EMSA. A 40-mer oligonucleotide containing p53 binding sites (5-AATTCT
CGAGCAGAACATGTCTAAGCATGCTGGGCTCGAG-3) derived from the
GADD45 promoter was labeled by using T4 polynucleotide kinase (New Eng-
land Biolabs). The radiolabeled strand was annealed with the complementary
strand, and an EMSA was performed as described previously (16). For the cold
oligonucleotide challenge experiment, the double-stranded unlabeled 40-mer
oligonucleotide containing wild-type or mutant p53 binding sites (5-AATTCT
CGAGCAGAAAATTTCTAAGAATTCTGGGCTCGAG-3) was used in ex-
cess (100- and 200-fold) over radiolabeled oligonucleotide containing wild-type
p53 binding sites.
For supershift assays, the indicated amounts of antibodies were added into the
reaction mix, and an EMSA was performed. In order to further elucidate the role
of PC4 in p53 DNA binding, the indicated amounts of p53 and its C-terminus-
specific antibody, PAb421, were incubated for 30 min prior to EMSA. Reaction
mixtures (40 l) contained 8 l of 5 EMSA buffer (100 mM HEPES at pH 7.9,
125 mM KCl, 0.5 mM EDTA, 50% glycerol, 10 mM MgCl2), 2 l of 60-g/ml
double-stranded poly(dI-dC), 4 l of bovine serum albumin (BSA) (1 mg/ml),
32P-labeled probe DNA (3 ng), proteins as indicated, and water to make up the
volume of 40 l. The reaction mixtures were incubated at 30°C for 30 min, and
the total volume of each reaction mixture was then loaded on a native 4%
polyacrylamide gel containing 0.5 Tris-borate–EDTA buffer and 0.05% NP-40
and electrophoresed at 4°C for 2 h (250 to 260 V). Similarly, for the DNA binding
experiment with Gal4-CTF1, the oligonucleotide containing the Gal4 binding
site (5-GTCTCTAGGTCGGAGTACTGTCCTCCGCGGAGACTCTAGA-
3) was radiolabeled and annealed with a complementary oligonucleotide. The
EMSA was performed as described previously (6). Briefly, the reaction mixture
(40 l), containing 20 mM HEPES (pH 7.5), 50 mM KCl, 5 mM MgCl2, 10 M
ZnCl2, 6% glycerol, 200 g of BSA/ml, 50 g of poly(dI-dC)/ml, and 3 ng of
32P-labeled DNA fragment, was incubated with proteins as indicated at 30°C for
30 min, and the total reaction mixture was then loaded on a native 6% poly-
acrylamide gel containing 0.5 Tris-borate–EDTA buffer. The gels were then
dried and exposed for autoradiography. DNA-protein complexes were quantified
with a PhosphorImage Analyzer (Fuji) using Image Guage software. Quantita-
tion of DNA binding data represents an average of three independent experi-
ments.
Immunoprecipitation and immunoblotting. Immunoprecipitation was per-
formed as described previously (32). Briefly, U2OS cells (p53/) were treated
with 2 g of adriamycin/ml for 24 h. After adriamycin treatment, the cells were
lysed in a buffer containing 10 mM HEPES-KOH (pH 7.9), 1.5 mM MgCl2, 10
mM KCl, 150 mM NaCl, 0.5 mM dithiothreitol, 1 mM phenylmethylsulfonyl
fluoride, 50 mM NaF, 0.2 mM sodium orthovanadate, 0.5 g of leupeptin/ml, 1.0
g of trypsin inhibitor/ml, 0.5 g of aprotinin/ml, and 40 g of pepstatin A/ml
and incubated on ice for 1 h. The cell debris was removed by centrifugation. The
protein content in the lysates was estimated by Bradford assay using a Bio-Rad
protein assay reagent (catalog no. 500-0006). An equal amount of protein from
each sample was subjected to immunoprecipitation by protein A-agarose beads
(GIBCO BRL) conjugated with either anti-p53 monoclonal antibody DO1
(Oncogene) or goat anti-PC4 polyclonal antibody N17 (Santa Cruz). Mouse
preimmune serum and goat preimmune serum were used as controls. The im-
munoprecipitated proteins were analyzed by Western blotting with the above-
mentioned antibodies as indicated in the figure legends.
GST pulldown assay. The GST pulldown assay was performed as described
previously (22). GST, GST-p53 (full-length), GST-p53(1-73) (p53 with amino
acids 1 to 73), GST-p53(120-290), GST-p53(284-330), GST-p53(328-368), and
GST-p53(364-393) were expressed in E. coli and conjugated to glutathione-
agarose beads as described elsewhere (11). The amounts of GST and GST fusion
proteins on the beads were normalized by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and staining with Coomassie brilliant blue
R-250 with BSA as a standard. Typically, 1 g of GST and GST-fusion proteins
was incubated with the E. coli lysate containing 200 ng of recombinant PC4 in a
final volume of 200 l of BC buffer (20 mM Tris HCl [pH 7.4], 20% glycerol, 0.2
mM EDTA, 0.1% NP-40) containing 150 mM KCl at 4°C for 2 h. The beads were
washed five times (1 ml each) with the incubation buffer and subjected to
SDS-PAGE analysis followed by immunoblotting with anti-PC4 polyclonal anti-
body N17 (Santa Cruz).
To analyze the nature of the PC4-induced p53-DNA complex, GST pulldown
assays were also performed with purified GST-p53 (500 ng) and PC4 (2 g)
either in the presence or absence of oligonucleotides containing p53 binding sites
(30 ng) in a total reaction volume of 400 l of BC buffer containing 60 mM KCl
at 4°C for 2 h. The presence of PC4 was detected by immunoblotting using
affinity-purified anti-PC4 polyclonal antibody.
Transfection assay. H1299 (p53 null) cells were maintained at 37°C in Dul-
becco’s modified Eagle medium with 10% fetal bovine serum. The mammalian
expression constructs of p53, p5330, Gal4-VP16, and PC4 used in this study
were placed under a cytomegalovirus (CMV) promoter. The p53-responsive
promoter PG13Luc contains 13 consensus p53-binding sites in tandem followed
by a polyomavirus promoter, which drives the luciferase gene (19). MDM2Luc
contains an MDM2 promoter-driven luciferase gene (8). These two constructs
were used to monitor the effect of PC4 on p53-mediated gene expression in vivo.
The CMV-driven -galactosidase (pCMV-gal) construct was used as an inter-
nal control. Prior to transfection, cells were seeded at 0.6  106 cells per
60-mm-diameter dishes and transfected with different plasmid constructs, using
Lipofectamine 2000 Plus (Invitrogen) according to the manufacturer’s protocol.
An empty vector was used to keep the total amount of DNA constant in each
transfection. Luciferase and -galactosidase activities were measured 24 h after
the transfection with luciferase assay and -galactosidase assay systems according
to the procedure provided by manufacturer (Promega). The transient transfec-
tion assay was performed three times independently to monitor average relative
luciferase activity.
Apoptosis assay. H1299 cells were seeded at 0.6  106 cells per 60-mm-
diameter dish 14 h prior to transfection. The cells were then transfected with the
indicated amounts (see figure legends) of mammalian expression constructs of
p53, p5330, and PC4 (either alone or in combination), using Lipofectamine
2000 Plus (Invitrogen) according to the manufacturer’s protocol. After 24 h of
transfection, the cells were fixed with 2.5% paraformaldehyde, stained with
Hoechst 33258, and observed under a fluorescence microscope by a blind ap-
proach. The quantitation of the number of apoptotic nuclei was performed by
counting 300 nuclei each time for three independent experiments.
Endogenous gene expression assay. H1299 cells were seeded at 1.5  106 cells
per 100-mm-diameter dish 14 h prior to transfection. Cells were transfected with
the indicated amounts of mammalian expression vectors containing full-length
p53, p5330, and PC4 either alone or in combination as described above. After
48 h, cells were lysed in a buffer containing 10 mM HEPES-KOH (pH 7.9), 1.5
mM MgCl2, 10 mM KCl, 250 mM NaCl, 0.5 mM dithiothreitol, 1 mM phenyl-
methylsulfonyl fluoride, 50 mM NaF, 0.2 mM sodium orthovanadate, 0.5 g of
leupeptin/ml, 1.0 g of trypsin inhibitor/ml, 0.5 g of aprotinin/ml, and 40 g of
pepstatin A/ml and incubated on ice for 1 h. The cell debris was removed by
centrifugation. The protein content of the lysate was estimated by Bradford assay
as described above. The cell lysates (containing 600 g of total cellular proteins)
were analyzed by SDS-PAGE (12%) followed by Western blotting using Bax
polyclonal antibody Ab4 (Oncogene), p53 monoclonal antibody DO1, and affin-
ity-purified PC4 polyclonal antibody.
RESULTS
Effect of PC4 on sequence-specific DNA binding of p53.
Most of the proteins that activate p53 function stimulate its
DNA binding to the cognate site. In our attempt to determine
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whether PC4 influences the sequence-specific DNA binding of
p53, we purified recombinant PC4 and FLAG-tagged p53 from
E. coli (Fig. 1A, lane 1, and 1B, lane 1). The authenticity of
these proteins was verified by Western blot analysis using the
respective antibodies (Fig. 1A, lane 2, and 1B, lane 2). We
tested the effect of PC4 on the DNA binding of p53 by EMSA
using a 40-mer double-stranded oligonucleotide containing the
p53 binding sites from the GADD45 promoter (16). The
EMSA analysis showed that 200 or 300 ng of PC4 in combi-
nation with 50 ng of p53 (the molar ratios for tertrameric p53
and dimeric PC4 were 1:7.7 and 1:11.5, respectively) efficiently
enhances (about two- and eightfold, respectively) p53 DNA
binding to its cognate site as compared to p53 alone (Fig. 1C,
lane 2 versus lanes 5 and 6). Apart from the predominant p53
complex, we also observed another complex when higher con-
centrations of PC4 (200 and 300 ng) were incubated with p53
(Fig. 1C, lanes 5 and 6). This could be attributed to a minor
degradation product of p53 whose DNA binding may be acti-
vated at the higher concentrations of PC4. However, we did
not observe an enhancement of p53 DNA binding when 50 and
100 ng of PC4 were added in combination with 50 ng of p53
(molar ratios for tertrameric p53 and dimeric PC4 were 1:1.9
and 1:3.8, respectively) (Fig. 1C, lane 2 versus lanes 3 and 4).
Since PC4 is a non-sequence-specific DNA binding protein,
low amounts are engaged in forming the probe-PC4 complex
(Fig. 1C and D, arrows; see also Discussion).
Under certain circumstances, p53 may also bind to the DNA
without any sequence specificity; hence, it is essential to inves-
tigate the specificity of p53 DNA binding to its cognate site. In
order to demonstrate that the activated complex is due to
sequence-specific binding of p53, we performed an EMSA with
an excess of cold competitor oligonucleotide containing wild-
type or mutant p53 binding sites (see Materials and Methods).
We observed that in the presence of cold oligonucleotide (100-
fold excess over radiolabeled oligonucleotide) containing wild-
type p53 binding sites, the formation of activated p53-DNA
complex was dramatically reduced (Fig. 1D, compare lanes 3
and 4). Further, increasing the wild-type cold oligonucleotide
(200-fold excess) almost completely abolished the DNA bind-
ing of p53 to its radiolabeled cognate sites (Fig. 1D, compare
lanes 3 and 5). On the other hand, even a 200-fold excess of
cold oligonucleotide containing mutant binding sites did not
affect the DNA binding of p53 to the radiolabeled probe (Fig.
1D, lane 3 versus lanes 6 and 7). These observations suggest
that the PC4-mediated enhancement of p53 DNA binding to
its cognate sites is sequence specific.
In vivo and in vitro interaction of PC4 and p53. PC4 inter-
acts with several activators, namely VP16, CTF1, Sp1, and
FIG. 1. PC4 activates sequence-specific DNA binding of p53. (A and B) Recombinant proteins were used in different experiments. (A) Lane
1, 300 ng of recombinant PC4 was analyzed by SDS–15% PAGE. Lane 2, authenticity of the PC4 was analyzed by Western blotting using anti-PC4
polyclonal antibody N17. (B) Lane 1, 100 ng of recombinant FLAG-tagged p53 was analyzed by SDS–10% PAGE. Lane 2, authenticity of the p53
was analyzed by Western blotting using anti-p53 monoclonal antibody PAb421. (C and D) Effect of PC4 in p53-mediated DNA binding.. (C) Three
nanograms of a 32P-labeled oligonucleotide containing a p53 binding site was incubated with 50 ng of p53 either in the absence of PC4 (lane 2)
or in the presence of 50 ng (lane 3), 100 ng (lane 4), 200 ng (lane 5), or 300 ng (lane 6) of PC4. The 32P-labeled oligonucleotide was also incubated
with 50 ng (lane 7), 100 ng (lane 8), 200 ng (lane 9), and 300 ng (lane 10) of PC4 alone. Lane 1 contains the 32P-labeled oligonucleotide alone.
(D) EMSA was done as described in the text in the presence of p53 (50 ng) either alone (lane 2) or in combination with PC4 (300 ng) (lane 3)
and competitor DNA (100 [lanes 4 and 6] and 200 [lanes 5 and 7]) containing wild-type (WT) (lanes 4 and 5) and mutant (mt) (lanes 6 and
7) p53 binding sites. Lane 1 contains 32P-labeled oligonucleotide alone.
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BRCA1, resulting in stimulation of activator-dependent tran-
scription (9, 14, 18). On the basis of these observations, we
hypothesized that PC4 may interact with p53 to facilitate re-
cruitment to its cognate DNA binding site. In order to inves-
tigate the possible interaction between the two proteins, p53
expression was induced in U2OS cells by adriamycin treatment
(2 g/ml for 24 h) (Fig. 2A, upper panel, compare lanes 1 and
2). It was observed that the amount of PC4 remained almost
the same before and after adriamycin treatment (Fig. 2A,
lower panel, lanes 1 and 2). Immunoprecipitation was per-
formed by incubating the drug-treated U2OS cell lysate with
protein A-agarose beads conjugated to either anti-p53 mouse
monoclonal antibody DO1 (Oncogene) or anti-PC4 goat poly-
clonal antibody N17 (Santa Cruz). Immunoprecipitation with
anti-p53 or anti-PC4 antibodies pulled down PC4 and p53,
respectively (Fig. 2B, lane 2, and 2C, lane 1). In contrast,
immunoprecipitation with the respective mouse and goat pre-
immune sera did not pull down PC4 or p53 nonspecifically
(Fig. 2B, lane 3, and 2C, lane 3). These data suggest that PC4
interacts with p53 in vivo.
As p53 is a protein with distinct functional domains, we
investigated the domain of p53 involved in the interaction with
PC4. For this purpose different GST-fused constructs of p53
(Fig. 2D) were expressed in bacteria and immobilized on glu-
tathione-agarose beads (Fig. 2E). These proteins were sub-
jected to GST pulldown assays (see Materials and Methods)
using a bacterial lysate containing full-length recombinant
PC4. It was observed that PC4 indeed interacts with p53, as
FIG. 2. PC4 directly interacts with p53 in vitro and in vivo. (A) Induction of p53 expression in the U2OS cell line. The levels of p53 and PC4
present in adriamycin (2 g/ml)-treated U2OS cells were assessed by Western blotting using anti-p53 (upper panel) and anti-PC4 (lower panel)
antibodies. (B and C) In vivo interaction of PC4 with p53. (B) Lane 1, an adriamycin (2 g/ml)-induced U2OS cell extract was immunoblotted with
polyclonal PC4 antibody N17. Lane 2, immunoprecipitation of endogenous PC4 from an induced U2OS cell lysate was performed using anti-p53
monoclonal antibody DO1 followed by immunoblotting with anti-PC4 polyclonal antibody. Lane 3, immunoprecipitation using mouse preimmune
serum used as a control. (C) Lane 1, immunoprecipitation of endogenous p53 from an induced U2OS cell extract, using anti-PC4 polyclonal
antibody N17 followed by immunoblotting with anti-p53 monoclonal antibody DO1. Lane 2, adriamycin-induced U2OS cell extract immunoblotted
with monoclonal p53 antibody DO1. Lane 3, immunoprecipitation reaction with goat preimmune serum used as a control. (D, E, and F) Interaction
of PC4 with p53 in an in vitro GST pulldown assay. (D) Schematic representation of GST and GST-p53 fusion proteins. , strong interaction
of PC4 with respective GST-p53 fusion protein;, weaker interaction;, no interaction. (E) SDS-PAGE (10%) and Coomassie blue R250 staining
of immobilized GST-p53 fusion proteins. Lane 1, GST-p53 (full length); lane 2, GST-p53(1-73), lane 3, GST-p53(120-290); lane 4, GST-p53(284-
330), lane 5, GST-p53(328-368); lane 6, GST-p53(364-393). GST fusion proteins predominantly contain intact proteins (indicated with asterisks)
with minimum low-molecular-weight breakdown products. (F) One microgram of GST (lane 2) or GST-p53 fusion proteins (lanes 3 to 8) was
incubated with bacterial extract containing 200 ng of PC4 and analyzed by immunoblotting with anti-PC4 N17 antibody. Lane 1, 5% input of
bacterial cell lysate. IP, immunoprecipitation; IB, immunoblot; WCE, whole-cell extract; AD, activation domain; DBD, DNA binding domain; OD,
oligomerization domain.
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observed in our previous immunoprecipitation experiments.
This further confirmed that the interaction is direct (Fig. 2F,
lane 3). We also found that residues 364 to 393 of the C-
terminal oligomerization domain of p53 strongly interacts with
PC4 (Fig. 2F, lane 8) while residues 120 to 290 of p53, spanning
the sequence-specific DNA binding domain, weakly interact
with PC4 (Fig. 2F, lane 5). Thus, PC4 directly interacts with
p53, consistent with similar observations for a number of other
transcriptional activators (as discussed above), for which it acts
as a general coactivator.
Involvement of PC4 in the activated complex. After estab-
lishing the fact that the direct interaction between PC4 and p53
stimulates the sequence-specific DNA binding of the latter, we
were interested in investigating whether PC4 is a part of the
activated complex. In order to address this possibility, the
components of the enhanced DNA-protein complex were an-
alyzed by supershift assay using different antibodies against p53
and PC4. The EMSA results showed that monoclonal p53
antibody PAb421 shifted the complex (Fig. 3A, lanes 4 and 7)
whereas antibodies specific to PC4 (N-terminus-specific anti-
body N17, C-terminus-specific antibody D18, and antibody
raised against full-length PC4) had a very minimal effect on
complex mobility. Among the three different antibodies against
PC4, D18 and polyclonal antibodies could shift the complex
distinctly, but the relative amount of the shifted complex was
found to be less than 10% compared to the total activated
complex (Fig. 3A, lanes 9 and 10). These results suggest that
PC4 may be a part of the DNA-protein complex, which is
either very poorly accessed by the antibodies or the protein
gets dissociated during electrophoresis. Yet another possibility
could be that PC4 forms a transient ternary complex. In order
to clarify this ambiguity, we performed a GST pulldown assay
in the presence or absence of oligonucleotide containing p53-
binding sites. If PC4 forms a transient ternary complex and
falls apart after recruitment of p53 to the cognate site, a GST
pulldown assay with GST-p53 in the presence of oligonucleo-
tide should not be able to detect PC4. However, the results
showed that GST-p53 efficiently pulls down PC4 even in the
presence of the oligonucleotide, which argues in favor of the
formation of a p53-DNA-PC4 ternary complex (Fig. 3B, com-
pare lanes 1 and 2). Furthermore, a nonspecific antibody
against p21 could not shift the complex (Fig. 3A, lanes 3 and
6), which confirmed the specificity of the supershift brought
about by the p53 antibody. Taken together, the data suggest
that PC4 stimulates the DNA binding of p53 to its cognate site
through the formation of a stable ternary complex with p53 and
DNA.
Effect of PC4 on sequence-specific DNA binding of p53 with
the C-terminal domain deleted. The C-terminal 30 amino acid
residues of p53, which strongly interact with PC4, negatively
regulate p53-mediated DNA binding (1, 16). Most of the p53
activators relieve the repression of this domain to activate p53
function (16) and thereby cannot activate p53 lacking the C-
terminal 30 amino acids. We investigated the role of this do-
main in PC4-mediated enhancement of p53 DNA binding. The
30 amino acid residues of p53 were masked by PAb421 (On-
cogene), and p53 was then subjected to EMSA using increasing
concentrations of PC4. Surprisingly, PC4 could enhance the
DNA binding of the antibody-masked p53 significantly (up to
about eightfold) (Fig. 4A, lane 4 versus lanes 5, 6, and 7). This
could indicate that PC4 stimulates DNA binding of p53 inde-
pendently of its interaction with the C-terminal domain. In
order to confirm this observation, we cloned, expressed, and
purified FLAG-tagged p5330 (Fig. 4B, lane 2). The authen-
ticity of p5330 was confirmed by Western blot analysis using
an N-terminus-specific antibody, DO1 (Fig. 4C, lanes 1 and 2),
and C-terminus-specific antibody, PAb421 (Fig. 4D, lanes 1
and 2). While the full-length p53 interacted with both antibod-
ies (Fig. 4C, lane 1, and 4D, lane 1), p53 with the C terminus
deleted was Western blotting positive only with DO1 (Fig. 4D,
compare lanes 1 and 2). Our EMSA analysis using 25 ng of
p5330 either alone or in combination with indicated amounts
of PC4 showed that the sequence-specific DNA binding of
recombinant p5330 was significantly enhanced (up to about
sixfold) (Fig. 4E, lane 2 versus lanes 3, 4, and 5). Though
PC4-mediated stimulation of p53 DNA binding does not seem
to require direct interaction between the C-terminal domain of
p53 and PC4, the role of the weaker interaction with the DNA
binding domain cannot be ruled out. Presumably, this interac-
tion plays an important role in the activation process during
the absence of the C-terminal domain of p53. This observation
suggests that similar to HMGB-1 (16), PC4 is also a unique
activator of p53-mediated DNA binding and activates p53
through a novel mechanism.
Role of PC4 in p53- and p5330-mediated gene expression
in vivo. It is a well-established fact that DNA binding by a
FIG. 3. PC4 forms a ternary complex with p53 and DNA.
(A) EMSA was done in presence of p53 (50 ng) and 32P-labeled
oligonucleotide (3 ng) containing a p53 binding site without antibody
(lane 2), with p21 antibody (500 ng) (lane 3), with p53 antibody (500
ng) (lane 4), with 250 ng of PC4 in the absence of any antibody (lane
5), or with 250 ng of PC4 with p21 antibody (500 ng) (lane 6), p53
antibody (500 ng) (lane 7), N-terminus-specific PC4 antibody N17 (2.5
g) (lane 8), C-terminus-specific PC4 antibody D18 (2.5 g) (lane 9),
or affinity-purified anti-PC4 polyclonal antibody raised against full-
length PC4 (2.5 g) (lane 10). Lane 1 contains 32P-labeled oligonucle-
otide alone. (B) A GST pulldown assay was performed (as described in
the legend to Fig. 2) with p53 (500 ng) and PC4 (2.5 g) either in the
absence (lane 1) or presence (lane 2) of cold oligonucleotide contain-
ing a wild-type p53 binding site from the GADD45 promoter. PC4 was
detected by Western blot analysis using affinity-purified anti-PC4 poly-
clonal antibody.
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sequence-specific transcription factor results in the recruit-
ment of RNA polymerase II machinery, leading to transcrip-
tional activation. It is therefore important to functionally cor-
relate the PC4-mediated stimulation of p53 DNA binding in
the context of transcriptional activation. In order to address
this, we performed transient transfection assays using the
H1299 (p53 null) cell line with two different p53-responsive
promoters, PG13Luc and MDM2Luc. Consistent with the re-
sults obtained in DNA binding experiments, PC4 in the pres-
ence of p53 could stimulate transactivation from both promot-
ers significantly (about sixfold for PG13Luc and about
eightfold for MDM2Luc) (Fig. 5A and B). However, the vector
control and PC4 alone showed negligible luciferase activity
(Fig. 5A and B). Since, PC4 also enhanced the DNA binding of
constitutively active p5330, we tested the ability of PC4 to
stimulate the p5330-mediated transactivation of PG13Luc
and MDM2Luc. Significantly, cotransfection of PC4 with
p5330 was found to activate transcription from both tem-
plates (about fivefold for PG13Luc and about eightfold for
MDM2Luc) as compared to transfection of p5330 alone (Fig.
5C and D). This observation further supports the DNA binding
data and suggests that PC4-mediated activation of p53 DNA
binding is unique and distinct from that of other p53 modula-
tors.
Presumably, in spite of being a unique activator of p53, the
mechanism of PC4-mediated transcriptional activation is
global. Consistent with this view, we found that PC4 could
indeed induce sequence-specific DNA binding of Gal4-CTF1
(up to about threefold) (Fig. 6A, lane 2 versus lanes 3 and 4)
in our system, as reported previously (9). Furthermore, PC4
could also stimulate Gal4-VP16-mediated reporter gene ex-
pression (up to about fourfold) from a Gal4-responsive pro-
moter, G10Luc (Fig. 6B).
PC4, being a global transcriptional coactivator, interacts
with a diverse and a constantly expanding array of transcrip-
tional activators and enhances activator-dependent transcrip-
tion. In the present study, we identified p53 as another activa-
tor whose function is regulated by PC4 through a unique
mechanism.
Physiological significance of PC4-mediated stimulation of
p53 function. p53 acts as a transcription factor by activating
several genes which facilitate the maintenance of normal cel-
lular growth and function (28, 29, 30). Thus, the enhancement
of p53-mediated transcriptional activity should lead to induc-
FIG. 4. Effect of PC4 on constitutively active p53. (A) PC4 activates p53 with the C-terminal domain masked. p53 (25 ng) and 32P-labeled
oligonucleotide containing a p53 binding site (3 ng) were incubated without any antibody (lane 2) or with nonspecific p21 antibody (250 ng) (lane
3) in an EMSA reaction (as described in the legend to Fig. 1). The C terminus of p53 (25 ng) was masked with p53 antibody PAb421 (250 ng) and
further incubated in an EMSA reaction (as described in the legend to Fig. 1) either alone (lane 4) or in combination with 100, 200, and 300 ng
of PC4 (lanes 5, 6, and 7, respectively). One hundred, 200, and 300 ng of PC4 alone (lanes 8, 9, and 10, respectively) were also incubated with
32P-labeled probe. Lane 1 contains only probe. (B) Purification of p5330. FLAG-tagged p53 (lane 1) and p5330 (lane 2) were purified from E.
coli BL21/pLys and stained with Coomassie brilliant blue R-250. (C and D) Western blot analyses were performed with N-terminus-specific
antibody DO1 and C-terminus-specific antibody PAb421 to check the authenticity of p53 (lane 1) and p5330 (lane 2). (E) Effect of PC4 on p5330
DNA binding. p5330 (10 ng) was incubated either alone (lane 2) or in the presence of 100, 200, and 300 ng of PC4 (lanes 3, 4, and 5, respectively)
along with 32P-labeled oligonucleotide containing a p53 binding site. One hundred, 200, and 300 ng of PC4 were incubated with the 32P-labeled
oligonucleotide (lanes 6, 7, and 8, respectively). Lane 1 contains 32P-labeled oligonucleotide probe alone.
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tion of either apoptosis or cell stasis as downstream physiolog-
ical effects. In order to validate the effects of PC4 on p53- and
p5330-mediated transcriptional activation of p53-responsive
promoters in a physiological environment, we wished to inves-
tigate the role of PC4 in induction of p53- and p5330-depen-
dent apoptosis. For this purpose, the H1299 (p53 null) cell line
was cotransfected with the indicated amounts of PC4 and p53
mammalian expression clones. After 24 h of transfection, cells
were stained with Hoechst 33258 and observed under a fluo-
rescence microscope to score the extent of nuclear fragmenta-
tion (Fig. 7A to F). The results showed that p53-dependent
apoptosis (as measured by the number of fragmented nuclei)
was enhanced by about twofold upon cotransfection of PC4
and p53 as compared to transfection of p53 alone (Fig. 7G).
Interestingly, we also observed that PC4 alone could minimally
stimulate apoptosis (Fig. 7G). In order to further confirm the
effect of PC4 on p53- or p5330-mediated apoptosis, we ana-
lyzed the expression of Bax (a proapoptotic target protein of
p53). Significantly, we observed that PC4 could induce p53-
and p5330-dependent Bax expression (up to about three- and
twofold, respectively) (Fig. 8, lane 5 versus lane 6 and lane 3
versus lane 4). Although our nuclear fragmentation assay data
showed that PC4 induces apoptosis minimally, we did not ob-
serve PC4-induced Bax expression. It is possible that higher
concentrations of PC4 may stimulate apoptosis through an
alternative pathway which does not involve Bax. These data
strongly correlate PC4-mediated activation of p53 DNA bind-
ing and reporter gene expression with their functional conse-
quence. This correlation leads to a very significant clue that
transcriptional coactivator PC4 may be involved in regulation
of p53-mediated apoptosis during DNA damage or cellular
stress.
DISCUSSION
p53 functions as a transcription factor to activate expression
of its target genes, which either induce cell cycle arrest or
apoptosis. To carry out its function, p53 interacts with several
coactivators, namely p300/CBP, PCAF, JMY, Zac1, HMGB-1,
and hTAF9, with distinct functional consequences (10, 11, 15,
31). In this study, we report that (i) PC4 (a transcriptional
coactivator in RNA polymerase II-mediated transcription) ac-
tivates sequence-specific DNA binding of p53 and interacts
with p53 in vitro and in vivo; (ii) the activated complex is
FIG. 5. PC4 stimulates p53- and p5330-mediated reporter gene expression in vivo. (A) H1299 (p53 null) cells were transiently transfected with
the mammalian expression constructs of p53 (250 ng) or PC4 (2.5 g) either alone or in combination. The p53-responsive promoter construct
pG13Luc (1 g) was used to measure the luciferase activity driven by p53. (B) H1299 cells were cotransfected with p53 (250 ng) or PC4 (4.5 g)
either alone or in combination. The reporter construct used was MDM2Luc (1 g). (C) p5330 (100 ng) or PC4 (2.5 g) was cotransfected either
alone or in combination with PG13Luc. (D) H1299 cells were cotransfected with p5330 (100 ng) or PC4 (4.5 g) either alone or in combination.
MDM2Luc (1 g) was used as the reporter construct. Equivalent amounts of control empty vectors were used to normalize the amount of
transfected DNA. pCMV-gal (1 g) was used as an internal control for all the transfection experiments to normalize luciferase activity. After
normalization, relative luciferase activity was plotted (y axis). The relative luciferase activity is represented as an average of triplicate samples.
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ternary in nature, containing PC4, p53, and DNA; (iii) it can
induce sequence-specific DNA binding of p5330; (iv) gene
expression regulated by p53 and p5330 is stimulated by PC4
in transient transfection assays from both synthetic and natural
p53-responsive promoters, which is reflected in the fact that
PC4 could induce p53-dependent apoptosis by stimulating bax.
These results have been discussed in relation to the fact that
this is the first report demonstrating a functional interaction of
PC4 with p53 and its physiological consequence.
The efficiency of p53 in functioning as a transcription factor
is modulated by its ability to bind its cognate DNA site, which
can be regulated by several interacting factors. PC4 interacts
with a diverse group of transcriptional activators and not only
enhances their DNA binding ability but also their transcrip-
tional activation (9). Surprisingly, p53, being one of the most
significant transcription factors for the maintenance of cellular
homeostasis, was not studied in conjunction with PC4. We
were interested in investigating the possible functional inter-
action of PC4 with p53 and found that PC4 could stimulate
sequence-specific DNA binding of p53 by about eightfold.
However, we found that a molar excess of PC4 was required
for the stimulation of p53 DNA binding. This requirement of
high amounts of PC4 can be easily explained by a careful
observation of the results of EMSA (Fig. 1C). PC4 is known to
have a non-sequence-specific DNA binding ability (9), which is
ratified by our data (Fig. 1C, lanes 7 to 10). The unbound DNA
probe in our experiments titrates out the PC4 that is required
to show an enhancement of p53 DNA binding. Therefore, the
excess of PC4 that remains after saturation of the free probe is
what causes the dramatic increase in p53 DNA binding.
PC4 also directly interacts with p53 to form a ternary com-
plex with p53 and DNA. Both the DNA binding (amino acid
residues 120 to 290) and the C-terminal (residues 364 to 393)
domains of p53 interact with PC4. The PC4-mediated stimu-
lation of p53 DNA binding is quite similar to that of several
other coactivators, as reported previously (9). Our data also
showed that PC4 could stimulate proline-rich activator Gal4-
CTF1- and the acidic activator Gal4-VP16-mediated DNA
binding and transactivation, respectively. These results suggest
that PC4-mediated activation of various transcription factors is
a global phenomenon. However, most interestingly, PC4 could
stimulate the sequence-specific DNA binding of p53 with the C
terminus deleted. Although the activation of p5330 DNA
binding by PC4 suggests that the stronger interaction between
residues 364 to 393 of p53 and PC4 is not essential for the
induction of p53-mediated DNA binding, the weaker interac-
tion between amino acid residues 120 to 290 of p53 and PC4
may play a significant role in this phenomenon. The weaker
interaction through the DNA binding domain of p53 with PC4
may also help in the recruitment of p53, especially in the
absence of the C-terminal 30 residues of p53. Presumably, PC4
changes the DNA structure to a favorable conformation for
p53 binding and recruits it through direct interaction. Mecha-
nistically, it might increase the specificity of p53 binding or
help it to monitor the DNA sequence for cognate sites.
In correlation with our DNA binding observations, we found
that PC4 could stimulate p53-dependent reporter gene expres-
sion from the synthetic (PG13Luc) as well as natural
(MDM2Luc) p53-responsive promoters. Interestingly, PC4
could also stimulate p5330-mediated transactivation from
both the p53-responsive promoters. Similar to findings for
HMGB-1 (16), these observations suggest that the PC4-medi-
ated activation of p53 function is not an ordinary activation
process wherein p53 activators negate the autoinhibitory func-
tion of the C-terminal domain and thus cannot stimulate DNA
binding of p5330. It would be interesting to elucidate further
the mechanism of PC4-mediated activation of p53.
HMGB-1 is a nonhistone chromatin protein that belongs to
the HMG superfamily. HMGB-1 is composed of two homol-
ogous HMG boxes (A and B) which are connected to an
extremely acidic C-terminal domain. Recently, we have shown
that both the A-box and the C-terminal domain are essential to
stimulate p53-mediated DNA binding, transactivation, and apo-
ptosis (3). HMGB-1 has an intrinsic DNA-bending property. It
provides prebent DNA to p53 and thereby enhances the effi-
ciency of p53 DNA binding to its cognate site (27). Like
HMGB-1, PC4 is also a nonspecific DNA binding protein
which can bind to both single-stranded and double-stranded
DNA. The double-stranded DNA binding domain of PC4 is
essential for transcriptional coactivation (9). It would be inter-
esting to investigate the requirement of different domains of
PC4 for stimulation of p53 DNA binding and whether the
DNA bending is responsible for this activation process.
Though PC4 functions as a general transcriptional coactiva-
tor for activator-dependent transcription, its role in a physio-
logical context has not yet been demonstrated. In the present
FIG. 6. PC4 is a global transcriptional coactivator. (A) PC4 stimu-
lates sequence-specific DNA binding of Gal4-CTF1. 32P-labeled oli-
gonucleotide (3 ng) containing a Gal4 binding site was incubated with
20 ng of Gal4- CTF1 either in the absence (lane 2) or presence of 100
ng (lane 3) or 200 ng (lane 4) of PC4. The 32P-labeled oligonucleotide
was also incubated with 100 ng (lane 5) or 200 ng (lane 6) of PC4 alone.
Lane 1 contains 32P-labeled oligonucleotide alone. (B) PC4 activates
Gal4-VP16-mediated reporter gene expression. H1299 cells were tran-
siently transfected with Gal4-VP16 (100 ng) or PC4 (4.5 g) either
alone or in combination. The Gal4-responsive promoter construct
G10Luc (1 g) was used to measure the luciferase activity driven by
Gal4-VP16. An equivalent amount of control parental vectors was
used to normalize the amount of transfected DNA. pCMV-gal (1 g)
was used as an internal control for all the transfection experiments to
normalize luciferase activity. After normalization, relative luciferase
activity was plotted (y axis). The relative luciferase activity is repre-
sented as an average of three individual experiments.
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report, we have addressed the biological relevance of PC4-
mediated stimulation of p53 DNA binding and transactivation.
Most of the p53 modulators induce p53-dependent apoptosis
by regulating its target apoptotic genes (28, 29, 30). We ob-
served that transiently expressed p53 and p5330, in combina-
tion with PC4, markedly enhanced p53- and p5330-depen-
dent apoptosis. Furthermore, it was also observed that
transient expression of p53 and p5330 in combination with
PC4 induces the expression of the p53-responsive proapoptotic
gene bax. These data are highly suggestive of a link between
PC4-mediated transcriptional activation and its physiological
effect in the cellular environment. Apart from the inhibition of
self-repression of AP2 (in a ras-transformed cell line) (18), our
study shows that PC4 might also play a key role in tumor
suppression by stimulating p53 function.
PC4 and p53 undergo posttranslational modification (phos-
phorylation and acetylation) with several functional conse-
quences (22, 26, 31). Phosphorylation of PC4 negatively regu-
lates its acetylation and coactivator function (22, 26), whereas
both acetylation and phosphorylation synergistically activate
p53 function (31). The posttranslational modifications of PC4
and p53 could be the key regulatory switch for PC4-mediated
p53 activation during genotoxic insult. The present study has
revealed a new role of PC4 in the regulation of tumor suppres-
sion. Further understanding of this novel function of PC4 will
establish a link between direct transcriptional activation and its
physiological consequences in greater detail.
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